A Caltech Library Service

Clinical Developments in Nanotechnology for Cancer Therapy

Heidel, Jeremy D. and Davis, Mark E. (2011) Clinical Developments in Nanotechnology for Cancer Therapy. Pharmaceutical Research, 28 (2). pp. 187-199. ISSN 0724-8741. doi:10.1007/s11095-010-0178-7.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


Nanoparticle approaches to drug delivery for cancer offer exciting and potentially "game-changing" ways to improve patient care and quality of life in numerous ways, such as reducing off-target toxicities by more selectively directing drug molecules to intracellular targets of cancer cells. Here, we focus on technologies being investigated clinically and discuss numerous types of therapeutic molecules that have been incorporated within nanostructured entities such as nanoparticles. The impacts of nanostructured therapeutics on efficacy and safety, including parameters like pharmacokinetics and biodistribution, are described for several drug molecules. Additionally, we discuss recent advances in the understanding of ligand-based targeting of nanoparticles, such as on receptor avidity and selectivity.

Item Type:Article
Related URLs:
Davis, Mark E.0000-0001-8294-1477
Additional Information:© 2010 Springer Science+Business Media, LLC. Received: 10 March 2010; Accepted: 19 May 2010; Published online: 12 June 2010.
Subject Keywords:clinical; nanoparticle; oncology; pharmacokinetics; targeting
Issue or Number:2
Record Number:CaltechAUTHORS:20110223-093924933
Persistent URL:
Official Citation:Clinical Developments in Nanotechnology for Cancer Therapy Jeremy D. Heidel and Mark E. Davis
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:22447
Deposited By: Ruth Sustaita
Deposited On:24 Feb 2011 16:20
Last Modified:09 Nov 2021 16:05

Repository Staff Only: item control page